<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05003908</url>
  </required_header>
  <id_info>
    <org_study_id>SC-10-ATG-11-01</org_study_id>
    <nct_id>NCT05003908</nct_id>
  </id_info>
  <brief_title>Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Diabetes</brief_title>
  <official_title>Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Foundation for Orthopaedics and Regenerative Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Foundation for Orthopaedics and Regenerative Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic&#xD;
      adult umbilical cord derived mesenchymal stem cells for the treatment of Diabetes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies have shown that stem cell treatment is safe and efficacious for the treatment of&#xD;
      Diabetes. Patients with Diabetes will receive a single intravenous infusion of cultured&#xD;
      allogeneic adult umbilical cord derived mesenchymal stem cells. The total dose will be 100&#xD;
      million cells. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24,&#xD;
      36, and 48 months post treatment for safety and efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (adverse events)</measure>
    <time_frame>Four year follow-up</time_frame>
    <description>Clinical monitoring of possible adverse events or complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: the level of A1C</measure>
    <time_frame>Four year follow-up</time_frame>
    <description>A1C blood test will be completed for each follow up point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: the level of C-Peptide</measure>
    <time_frame>Four year follow-up</time_frame>
    <description>C-Peptide test will be completed for each follow up point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Insulin dose reduction</measure>
    <time_frame>Four year follow-up</time_frame>
    <description>Changes of insulin dosage for each follow up point.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous infusion of 100 million cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloRx</intervention_name>
    <description>cultured allogeneic adult umbilical cord derived mesenchymal stem cells</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Diabetes&#xD;
&#xD;
          -  Understanding and willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Active cancer&#xD;
&#xD;
          -  Chronic multisystem organ failure&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Clinically significant Abnormalities on pre-treatment laboratory evaluation&#xD;
&#xD;
          -  Medical condition that would (based on the opinion of the investigator) compromise&#xD;
             patient's safety.&#xD;
&#xD;
          -  Continued drug abuse&#xD;
&#xD;
          -  Pre-menopausal women not using contraception&#xD;
&#xD;
          -  Previous organ transplant&#xD;
&#xD;
          -  Hypersensitivity to sulfur&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chadwick Prodromos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Foundation for Orthopaedics and Regenerative Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Surgical Associates Center</name>
      <address>
        <city>St. John's</city>
        <country>Antigua and Barbuda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chadwick Prodromos, M.D.</last_name>
      <phone>8476996810</phone>
      <email>research@ismoc.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Antigua and Barbuda</country>
  </location_countries>
  <reference>
    <citation>Hu J, Yu X, Wang Z, Wang F, Wang L, Gao H, Chen Y, Zhao W, Jia Z, Yan S, Wang Y. Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocr J. 2013;60(3):347-57. Epub 2012 Nov 16.</citation>
    <PMID>23154532</PMID>
  </reference>
  <reference>
    <citation>Jiang R, Han Z, Zhuo G, Qu X, Li X, Wang X, Shao Y, Yang S, Han ZC. Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. Front Med. 2011 Mar;5(1):94-100. doi: 10.1007/s11684-011-0116-z. Epub 2011 Mar 17.</citation>
    <PMID>21681681</PMID>
  </reference>
  <reference>
    <citation>Cai J, Wu Z, Xu X, Liao L, Chen J, Huang L, Wu W, Luo F, Wu C, Pugliese A, Pileggi A, Ricordi C, Tan J. Umbilical Cord Mesenchymal Stromal Cell With Autologous Bone Marrow Cell Transplantation in Established Type 1 Diabetes: A Pilot Randomized Controlled Open-Label Clinical Study to Assess Safety and Impact on Insulin Secretion. Diabetes Care. 2016 Jan;39(1):149-57. doi: 10.2337/dc15-0171. Epub 2015 Dec 1.</citation>
    <PMID>26628416</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>stem cell treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

